PrecigenPGEN
About: Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Employees: 25
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
7,139% more call options, than puts
Call options by funds: $4.13M | Put options by funds: $57K
47% more capital invested
Capital invested by funds: $84.7M [Q4 2024] → $124M (+$39.7M) [Q1 2025]
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
4% more funds holding
Funds holding: 131 [Q4 2024] → 136 (+5) [Q1 2025]
1.43% more ownership
Funds ownership: 25.87% [Q4 2024] → 27.3% (+1.43%) [Q1 2025]
19% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 42
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JMP Securities Jason Butler | 228%upside $6 | Market Outperform Reiterated | 12 Jun 2025 |
Financial journalist opinion









